ScreenerHero

NXTCNextCure, Inc.

NAS · US · Healthcare · Biotechnology · nextcure.com
6.290USD-7.23%Mkt Cap: 28.79M $P/E: —

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap28.79M $
Enterprise Value13.19M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-55.84M $
Revenue/Share—
Last Price6.290 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS65343E1082
Valuation
P/E (Trailing)—
P/E (Forward)-1.09
PEG—
EV/EBITDA-0.35
EV/Revenue—
P/S—
P/B2.09
EPS (TTM)-7.67
EPS (Forward)-5.76
52W Range
1.55033% of range15.74
52W High15.74 USD
52W Low1.550 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-159.81%
ROA-111.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.61M $
CapEx (TTM)—
FCF Margin—
FCF Yield-80.22%
Net Debt-15.42M $
Net Debt/EBITDA0.41
Balance Sheet
Debt/Equity0.15
Current Ratio3.47
Quick Ratio3.15
Book Value/Sh2.986 USD
Cash/Share4.389 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 14, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)22.50 USD
Upside (mean)+257.7%
Target Range20.00 USD – 25.00 USD
$20.00+257.7% to mean$25.00
# Analysts2
Ownership
Shares Out.4.58M
Float2.93M
Insiders8.64%
Institutions36.96%
Short Interest
Short Ratio0.0d
Short % Float3.09%
Short % Out.3.09%
Shares Short141.25K
Short (prev mo.)158.59K
Technical
SMA 504.164 (+51.1%)
SMA 2009.260 (-32.1%)
Beta1.27
S&P 52W Chg18.16%
Avg Vol (30d)4.32M
Avg Vol (10d)361.77K
Technical Indicators
RSI (14)53.2
MACD0.8172
MACD Signal0.7819
MACD Hist.+0.0353
BB Upper8.698 USD
BB Middle5.951 USD
BB Lower3.205 USD
BB Width92.30%
ATR (14)0.9542 USD
Vol Ratio (20d)0.09x